Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron will webcast its September 14, 2026 investor conference presentation for online access via its website.
Rhea-AI Summary
Longeveron (LGVN) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026.
The company’s presentation is scheduled for Monday, September 14, 2026, from 1:00–1:30 p.m. ET. A webcast of the presentation will be available via the “Events and Presentations” section of Longeveron’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 24 | Reverse stock split | Negative | -18.0% | Company announced a 1-for-10 reverse stock split effective August 26. |
| Aug 19 | CFO appointment | Neutral | +0.5% | Nirav Jhaveri became CFO and succeeded Marie Washburn. |
| Aug 12 | 2Q26 earnings report | Negative | -4.9% | Quarterly loss widened while revenue declined year over year. |
| Aug 11 | XPRIZE award | Positive | -7.4% | Company received a $1,000,000 Milestone 2 award as an XPRIZE finalist. |
| Aug 03 | Earnings scheduling notice | Neutral | +1.4% | Company scheduled second-quarter results and a conference call for August 12. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed negative reactions to the August 24 reverse split, August 12 results, and August 11 award announcement, while the August 19 CFO appointment was followed by a 0.45% gain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026 in New York City.
Details for the Company’s presentation:
| Date: | Monday, September 14, 2026 | |
| Time: | 1:00 – 1:30 p.m. ET | |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
